Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Calcitonin Gene Related Peptide (CGRP) - Overview Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development Alder Biopharmaceuticals Inc Eli Lilly and Co Serometrix LLC Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide (CGRP) - Drug Profiles AFAP-3 - Drug Profile Product Description Mechanism Of Action R&D Progress eptinezumab - Drug Profile Product Description Mechanism Of Action R&D Progress fremanezumab - Drug Profile Product Description Mechanism Of Action R&D Progress galcanezumab - Drug Profile Product Description Mechanism Of Action R&D Progress NOXL-41 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit CGRP for Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Calcitonin Gene Related Peptide (CGRP) - Dormant Products Calcitonin Gene Related Peptide (CGRP) - Discontinued Products Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones Featured News & Press Releases Feb 02, 2018: European Medicines Agency (EMA) Accepts Fremanezumab Marketing Authorization Application Jan 08, 2018: Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention Dec 18, 2017: FDA Accepts Biologics License Application for Fremanezumab with Priority Review for Prevention of Migraine and Grants Fast Track Designation for Cluster Headache Development Program Dec 11, 2017: FDA Accepts Biologics License Application to Review Galcanezumab for the Prevention of Migraine in Adults Nov 29, 2017: The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine Oct 17, 2017: Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA Sep 09, 2017: Teva Showcases Data Demonstrating Potential of Fremanezumab to Address Significant Unmet Need in Patients with Chronic and Episodic Migraine Sep 08, 2017: IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results For Up To 12 Months In Patients With Migraine Sep 07, 2017: Alder BioPharmaceuticals to Present Data from Eptinezumab Development Program at 18th Congress of the International Headache Society Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society Sep 05, 2017: Teva to Present Fremanezumab Data on Migraine Prevention at the 18th Congress of the International Headache Society Jun 27, 2017: Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine Jun 10, 2017: Lilly's Galcanezumab Significantly Reduces Number Of Migraine Headache Days For Patients With Migraine: New Results Presented At AHS Jun 08, 2017: Lilly To Present Late-Breaking Data For Galcanezumab At The American Headache Society Annual Scientific Meeting Jun 07, 2017: Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Alder Biopharmaceuticals Inc, H1 2018 Pipeline by Eli Lilly and Co, H1 2018 Pipeline by Serometrix LLC, H1 2018 Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018 Dormant Projects, H1 2018 Discontinued Products, H1 2018List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018